Provided By GlobeNewswire
Last update: Oct 2, 2025
EMERYVILLE, Calif. and UTRECHT, The Netherlands and PHILADELPHIA, Oct. 02, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (“XOMA Royalty”) (NASDAQ: XOMA) and LAVA Therapeutics N.V. (“LAVA”) (Nasdaq: LVTX) today announced the extension of the expiration of the tender offer to purchase all outstanding shares of common shares of LAVA, for (i) a cash amount to be determined in accordance with the Purchase Agreement, plus (ii) a non-transferable contingent value right (“CVR”) per share representing the right to receive 75% of the net proceeds related to LAVA’s two partnered assets and 75% of any net proceeds from any out license or sale of LAVA’s unpartnered programs (the “Offer”).
Read more at globenewswire.comNASDAQ:XOMA (12/1/2025, 1:26:53 PM)
31.39
-0.74 (-2.3%)
XOMA ROYALTY CORP - XOMA 8 3/8 PERP
NASDAQ:XOMAO (12/1/2025, 11:27:58 AM)
25.45
-0.02 (-0.08%)
XOMA ROYALTY CORP - XOMA 8 5/8 PERP
NASDAQ:XOMAP (12/1/2025, 10:30:39 AM)
26.5
-0.12 (-0.45%)
Find more stocks in the Stock Screener


